

Søren H Sindrup

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7351939/publications.pdf>

Version: 2024-02-01

39
papers

3,063
citations

516710

16
h-index

315739

38
g-index

39
all docs

39
docs citations

39
times ranked

2406
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. <i>Pain</i> , 1999, 83, 389-400.	4.2	994
2	Antidepressants in the Treatment of Neuropathic Pain. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 96, 399-409.	2.5	472
3	The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study. <i>Pain</i> , 2014, 155, 2263-2273.	4.2	367
4	The hypoalgesic effect of tramadol in relation to CYP2D6*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 636-644.	4.7	346
5	Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 686-693.	4.7	175
6	Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 509-515.	4.7	134
7	Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. <i>Brain</i> , 2021, 144, 1632-1645.	7.6	81
8	Imipramine and pregabalin combination for painful polyneuropathy. <i>Pain</i> , 2015, 156, 958-966.	4.2	57
9	Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 245-251.	4.7	55
10	The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: A randomised, controlled trial. <i>European Journal of Pain</i> , 2006, 10, 567-567.	2.8	51
11	The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 636-641.	4.7	45
12	St. John's wort has no effect on pain in polyneuropathy. <i>Pain</i> , 2001, 91, 361-365.	4.2	43
13	Original research: Second IVIg course in Guillain-BarrÃ© syndrome with poor prognosis: the non-randomised ISID study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 113-121.	1.9	34
14	Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2018, 57, 70-76.	2.2	27
15	Guillain-BarrÃ© syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. <i>Journal of Neurology</i> , 2019, 266, 440-449.	3.6	27
16	The sixâspotâstep test â a new method for monitoring walking ability in patients with chronic inflammatory polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 131-138.	3.1	20
17	Tailored treatment of peripheral neuropathic pain. <i>Pain</i> , 2012, 153, 1781-1782.	4.2	13
18	Effect of lacosamide in peripheral neuropathic pain: study protocol for a randomized, placebo-controlled, phenotype-stratified trial. <i>Trials</i> , 2019, 20, 588.	1.6	13

#	ARTICLE	IF	CITATIONS
19	A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. <i>Muscle and Nerve</i> , 2020, 61, 316-324.	2.2	12
20	Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, e1111.	6.0	12
21	Diagnostic yield by testing small fiber function in patients examined for polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2001, 6, 214-218.	3.1	9
22	A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 64-71.	3.1	9
23	Oxaliplatin Neuropathy: Predictive Values of Skin Biopsy, QST and Nerve Conduction. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 679-688.	2.6	7
24	Factors with impact on magnitude of the placebo response in randomized, controlled, cross-over trials in peripheral neuropathic pain. <i>Pain</i> , 2020, 161, 2731-2736.	4.2	7
25	Test-retest and time dependent variation and diagnostic values of vibratory sensation determined by biothesiometer and the Rydel-Seiffer tuning fork. <i>Brain and Behavior</i> , 2021, 11, e2230.	2.2	6
26	Association Between Incident Cancer and Guillain-Barré Syndrome Development: A Nationwide Case-Control Study. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200015.	1.1	6
27	Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 637-640.	2.1	5
28	Association of Hospital-Diagnosed Infections and Antibiotic Use with Risk of Developing Guillain-Barré Syndrome. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000011342.	1.1	5
29	Impact of variability in baseline pain on the placebo response in randomized, placebo-controlled, crossover trials in peripheral neuropathic pain. <i>Pain</i> , 2021, Publish Ahead of Print, .	4.2	5
30	Normative reference values for the dorsal sural nerve derived from a large multicenter cohort. <i>Clinical Neurophysiology Practice</i> , 2021, 6, 239-243.	1.4	5
31	Painful diabetic polyneuropathy and quality of life in Danish type 2 diabetic patients. <i>Scandinavian Journal of Pain</i> , 2017, 16, 173-173.	1.3	4
32	A randomized, controlled trial of a β 2-agonist in painful polyneuropathy. <i>Pain</i> , 2021, 162, 1364-1373.	4.2	4
33	Nicotinic acetylcholine receptor agonism: Progress in the management of neuropathic pain?. <i>Pain</i> , 2009, 146, 227-228.	4.2	3
34	The Impact of Serum Drug Concentration on the Efficacy of Imipramine, Pregabalin, and their Combination in Painful Polyneuropathy. <i>Clinical Journal of Pain</i> , 2017, 33, 1047-1052.	1.9	3
35	Placebo responses in patients with peripheral neuropathic pain. <i>Scandinavian Journal of Pain</i> , 2014, 5, 210-210.	1.3	2
36	Diagnostic value of near-nerve recordings of the sural nerve in polyneuropathy patients. <i>Clinical Neurophysiology</i> , 2016, 127, 1741-1743.	1.5	2

#	ARTICLE	IF	CITATIONS
37	The additional diagnostic value of motor nerve excitability testing in chronic axonal neuropathy. <i>Clinical Neurophysiology Practice</i> , 2022, 7, 27-33.	1.4	2
38	Immunostaining of skin biopsy adds no diagnostic value in MGUS-associated peripheral neuropathy. <i>Journal of the Neurological Sciences</i> , 2015, 349, 60-64.	0.6	1
39	Long-term follow-up of facilitated subcutaneous immunoglobulin therapy in multifocal motor neuropathy. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117495.	0.6	0